SAN FRANCISCO, Jan. 13, 2017 /PRNewswire/ -- J.P. Morgan 35th Annual Healthcare Conference 2017 -- Viriom, Inc. (San Diego, CA) today announced positive 48 week clinical findings for Elsulfavirine (ESV) vs Efavirenz (EFV) in combination with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). The Elsulfavirine (ESV) 20 mg-based ART regimen was equally efficacious but significantly better tolerated than EFV 600 mg-based regimen. The results will be presented at a major scientific conference next month.
About Viriom, Inc.
Hope - Health - Happiness We are an emerging leader in the development of innovative antiviral drugs, drug combinations and diagnostics. Viriom is passionate about bringing effective and affordable cures for life threatening viral infections such as HIV, viral hepatitis, and tropical fevers to patients around the globe. Viriom's most advanced drug, Elsulfavirine (ESV), is a once-daily oral prodrug of VM1500A, a novel, potentially best in class HIV NNRTI. Viriom expects to obtain first market authorizations for Elsulfavirine (ESV) outside of the US in 2017. Development is underway for once-weekly oral PrEP and long-acting injectable (subcutaneous and intramuscular) formulations for Elpida/VM1500A, as well as fixed drug combination formulations. Viriom sponsors and conducts joint research programs on immunotherapies and epigenetic approaches to combat viral infections with NIH intramural research laboratories, The Scripps Research Institute (La Jolla, CA), Heidelberg University (Germany) and Fox Chase Cancer Center (Philadelphia, PA)
Learn more: viriom.com @viriominc #hopehealthhappiness #accessforeverybody